XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program

Summary

**media[1229066]**Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities.Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC.MPER vaccine immunogens elicit antibody levels approximately five times those of the study comparator in rhesus macaques; antisera retain antiviral activity at a 1:1,000 dilution.BOSTON and SHENZHEN, China, Sept. 23, 2026 /PRNewswire/ -- XtalPi (HKEX: 2228) announced that Viva-Thera, a biotechnology company it incubated and backs as a strategic shareholder, has nominated a preclinical candidate (PCC) targeting the membrane-proximal external region (MPER) of HIV-1 gp41. The partners completed discovery and optimization in seven months by combining Viva-Thera's atomic-resolution structural research with XtalPi's AI drug design and automation platform. In its public debut, Viva-Thera also reported functional vaccine results in rhesus macaques and progress in targeted gene delivery. The company is pursuing HIV prevention and cure through four modalities-vaccines, long-acting small molecules, gene therapy and cell therapy-with XtalPi providing computational design, predictive modeling and experimental automation across the portfolio.